TOTECT Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Totect, and when can generic versions of Totect launch?

Totect is a drug marketed by Clinigen and is included in one NDA.

The generic ingredient in TOTECT is dexrazoxane hydrochloride. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the dexrazoxane hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Totect

A generic version of TOTECT was approved as dexrazoxane hydrochloride by HIKMA on September 28^th, 2004.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for TOTECT?
What are the global sales for TOTECT?
What is Average Wholesale Price for TOTECT?

Summary for TOTECT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	10
Patent Applications:	393
Drug Prices:	Drug price information for TOTECT
What excipients (inactive ingredients) are in TOTECT?	TOTECT excipients list
DailyMed Link:	TOTECT at DailyMed

Drug patent expirations by year for TOTECT

Recent Clinical Trials for TOTECT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
M.D. Anderson Cancer Center	Phase 2
EsPhALL network I-BFM Study Group	Phase 3
Children's Oncology Group	Phase 3

See all TOTECT clinical trials

US Patents and Regulatory Information for TOTECT

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Clinigen	TOTECT	dexrazoxane hydrochloride	INJECTABLE;INJECTION	022025-001	Sep 6, 2007		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for TOTECT

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Clinigen	TOTECT	dexrazoxane hydrochloride	INJECTABLE;INJECTION	022025-001	Sep 6, 2007	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for TOTECT

See the table below for patents covering TOTECT around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Germany	1162981		⤷ Sign Up
Russian Federation	2252761	ЛЕЧЕНИЕ СЛУЧАЙНОЙ ТРАНССУДАЦИИ АНТРАЦИКЛИНОВ (THERAPY OF SPORADIC TRANSUDATION OF ANTHRACYCLINES)	⤷ Sign Up
European Patent Office	1162981	DEXRAZOXANE POUR LE TRAITEMENT D'EPANCHEMENT ACCIDENTEL D'ANTHRACYCLINES (DEXRAZOXANE FOR THE TREATMENT OF ACCIDENTAL EXTRAVASATION OF ANTHRACYCLINES)	⤷ Sign Up
China	1346275		⤷ Sign Up
Australia	3272600		⤷ Sign Up
Japan	4422916		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for TOTECT

Recent Clinical Trials for TOTECT

Make Better Decisions: Try a trial or see plans & pricing